Oncolytics Biotech Inc.

What they do

Oncolytics develops pelareorep, a proprietary isolate of reovirus, a naturally occurring non-pathogenic double-stranded RNA virus, delivered intravenously. The company states pelareorep selectively replicates in tumors, activates innate and adaptive immune responses and weakens tumor defense mechanisms, making tumors more susceptible to chemotherapies, checkpoint inhibitors and other immuno-oncology approaches. Its primary focus is positioning pelareorep as a platform immunotherapy for gastrointestinal cancers, with investigator-sponsored and registrational opportunities in metastatic colorectal, second-line or later anal, and metastatic pancreatic cancer.

Revenue drivers

• Pelareorep product candidate — No product revenue; pelareorep remains in clinical development and has not received regulatory approval, so the company reports no significant revenue from it.
• Registration-enabled GI programs — Value is tied to advancing pelareorep in metastatic colorectal, anal and pancreatic cancer toward registration; no revenue is generated today.
• Partnerships and strategic alliances — Strategy includes collaborations with biopharmaceutical companies and laboratories that could complement development, but no completed partnership revenue is disclosed in the excerpts.
• Financing arrangements — Operations are funded through capital raising, including an at-the-market equity sales agreement and potential strategic collaborations, rather than product sales.

Recent performance

Oncolytics reported annual net losses of $22.8M in 2024 and $28.8M in 2025, with diluted EPS of $-0.3 in both years. Operating cash flow was negative $19.9M in 2024 and negative $20.1M in 2025. At June 30, 2026, total assets were $7.7M, total liabilities $13.8M, shareholders' equity was negative $6.2M, and cash and cash equivalents were $4.1M.

Strategy

The company's stated strategy is to develop and seek regulatory approval for pelareorep, pursue partnerships allowing faster and more efficient development, and access additional technologies where beneficial. Management says it continues assessing pelareorep's safety and efficacy in human subjects, maintaining and establishing collaborations, and forming strategic alliances that could eventually add sales and marketing capabilities. It focuses on gastrointestinal cancers and advancing GI programs to registration-enabled studies, and has received Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI in second-line metastatic colorectal cancer.

Risks

• Going concern — Management states existing cash resources are not sufficient to fund planned operations for at least twelve months from issuance of the financial statements, raising substantial doubt about the ability to continue as a going concern.
• No approved product — Pelareorep is in the research and development stage and will require later-stage and pivotal trials and a successful BLA or comparable foreign submission before it can be marketed.
• Need for additional financing — Continuation as a going concern depends on raising additional capital, and there is no assurance financing will be available on acceptable terms or at all.
• Listing and governance events — Recent 8-K events include a delisting notice or listing-rule failure on 2026-07-24, a change in accountants on 2026-07-08, and a director or officer change on 2026-06-02.

Outlook

Management expects to continue incurring losses as it advances pelareorep and states it does not expect significant revenues unless and until the product receives regulatory approval and becomes commercially viable. It plans to fund operations through its at-the-market equity sales agreement, potential strategic collaborations or other financing arrangements, while exploring registrational studies and investigator-sponsored trials in metastatic colorectal, second-line or later anal, and metastatic pancreatic cancer. Management notes no assurance that additional financing will be available when needed or on acceptable terms.